



1 **SARS-CoV-2 RNA and antibody detection in human milk from a prospective**
2 **multicenter study in Spain**

3

4 Christine Bäuerl¹, Walter Randazzo², Gloria Sánchez², Marta Selma-Royo¹, Elia Garcia-
5 Verdevio³, Laura Martínez-Rodríguez⁴, Anna Parra-Llorca⁵, Carles Lerin⁶, Victoria Fumadó⁷,
6 Francesca Crovetto⁸, Fátima Crispi⁸, Francisco J Pérez-Cano⁹, Gerardo Rodríguez¹⁰, Gema Ruíz-
7 Redondo¹¹, Cristina Campoy¹², Cecilia Martínez-Costa⁴ , Maria Carmen Collado¹  on behalf of
8 MilkCORONA study team

9 ¹Department of Biotechnology, Institute of Agrochemistry and Food Technology- National
10 Research Council (IATA-CSIC), Paterna, Valencia, Spain.

11 ²Department of Preservation and Food Safety Technologies, Institute of Agrochemistry and
12 Food Technology- National Research Council (IATA-CSIC), Valencia, Spain.

13 ³Department of Gynecology and Obstetrics, Hospital Universitario Doctor Peset, Valencia,
14 Spain.

15 ⁴Department of Pediatrics, Hospital Clínico Universitario, University of Valencia, Spain.
16 Nutrition Research Group of INCLIVA, Valencia, Spain.

17 ⁵Health Research Institute La Fe, Neonatal Research Group, Spain and University and
18 Polytechnic Hospital La Fe, Division of Neonatology, Valencia, Spain.

19 ⁶Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain.

20 ⁷Infectious Diseases Unit Department of Pediatrics, Sant Joan de Deu University Hospital,
21 Barcelona, Spain

22 ⁸BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Sant Joan de
23 Deu and Hospital Clínic), IDIBAPS, University of Barcelona, Barcelona, Spain.

24 ⁹Physiology Section, Department of Biochemistry and Physiology, Faculty of Pharmacy and
25 Food Science, University of Barcelona (UB), Barcelona, Spain.


26 ¹⁰Departament of Pediatrics, University of Zaragoza, Hospital Clínico Universitario Lozano
27 Blesa, Zaragoza. Instituto de Investigación Sanitaria Aragón (IIS Aragón), Red de Salud Materno
28 Infantil y del Desarrollo (SAMID), Spain

29 ¹¹Department of Obstetrics and Gynaecology. University Hospital Clinic “San Cecilio” – Health
30 Sciences Technological Park (PTS), Granada, Spain.

31 ¹²Department of Pediatrics, School of Medicine, University of Granada, Granada, Spain.

32

33

34  shared senior authorship

35 *Correspondence to: MCC (mcolam@iata.csic.es), Institute of Agrochemistry and Food
36 Technology, Spanish National Research Council (IATA-CSIC), Department of Biotechnology. Av.
37 Agustín Escardino 7, 46980 Valencia, Spain. Phone: +34 963900022

38

39

40

1

2 **Abstract/Summary**

3 Background: During the COVID-19 pandemic in 2020, breastfeeding in women positive for
4 SARS-CoV-2 was compromised due to contradictory data regarding potential viral
5 transmission. However, growing evidence confirms the relevant role of breast milk in providing
6 passive immunity by generating and transmitting specific antibodies against the virus. Thus,
7 our study aimed to develop and validate a specific protocol to detect SARS-CoV-2 in breast
8 milk matrix as well as to determine the impact of maternal SARS-CoV-2 infection on presence,
9 concentration, and persistence of specific SARS-CoV-2 antibodies.

10 Study design/Methods: A prospective multicenter longitudinal study in Spain was carried out
11 from April to December 2020. A total of 60 mothers with SARS-CoV-2 infection and/or
12 recovered from COVID-19 were included (n=52 PCR-diagnosed and n=8 seropositive). Data
13 from maternal-infant clinical records and symptomatology were collected. A specific protocol
14 was validated to detect SARS-CoV-2 RNA in breast milk, targeting the N1 region of the
15 nucleocapsid gene and the envelope (E) gene. Presence and levels of SARS-CoV-2 specific
16 immunoglobulins (Igs) -IgA, IgG, and IgM- in breast milk samples from COVID-19 patients and
17 from 13 women before the pandemic were also evaluated.

18 Results: All breast milk samples showed negative results for SARS-CoV-2 RNA presence. We
19 observed high intra- and inter-individual variability in the antibody response to the receptor-
20 binding domain (RBD) of the SARS-CoV-2 spike protein for each of the three isotypes IgA, IgM
21 and IgG. Protease domain (MPro) antibodies were also detected in milk. In general, 82.9 % of
22 the milk samples were positive for at least one of the three antibody isotypes, being 52.86 % of
23 those positive for all three Igs. Positivity rate for IgA was relatively stable over time (65.2 –
24 87.5 %), whereas it raised continuously for IgG (47.8 % the first ten days to 87.5 % from day 41
25 up to day 206 post-PCR confirmation).

26 Conclusions: Considering the lack of evidence for SARS-CoV-2 transmission through breast
27 milk, our study confirms the safety of breastfeeding practices and highlights the relevance of
28 virus-specific SARS-CoV-2 antibody transfer, that would provide passive immunity to breastfed
29 infants and protect them against COVID-19 disease. This study provides crucial data to support
30 official breastfeeding recommendations based on scientific evidence.

31

32

33 **Keywords:** breast milk, SARS-CoV-2, antibodies, immunoglobulins, breastfeeding

34

35

36

37

1

2 INTRODUCTION

3 Breastfeeding is considered the gold standard for infant feeding and is of crucial importance in
4 influencing both infant growth and development, as well as in preventing future diseases
5 during adulthood. Breast milk is a biological, complex, and living food that adapts to the
6 specific nutritional and immunological requirements of the developing infant. Compared with
7 formula feeding, exclusive breastfeeding has been consistently associated with lower
8 morbidity and mortality during the first year of life, as well as with reduced incidence and
9 severity of infections and immune-related diseases. Epidemiological studies have
10 demonstrated that breastfeeding decreases risk of viral and bacterial infections, allergies, and
11 obesity in infants [1–4]. Due to its beneficial effects, international organizations including the
12 World Health Organization (WHO), the American Academy of Pediatrics (AAP), and European
13 Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Committee on
14 Nutrition recommend exclusive breastfeeding for the first six months of life, and continuing
15 breastfeeding while complementary foods are introduced until 2 years of age or beyond [5].

16 The global pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute
17 respiratory syndrome coronavirus 2 (SARS-CoV-2), has increased the concerns on its mother-
18 to-child transmission, including breastfeeding route. Currently, the scientific debate on
19 whether breast milk could be a transmission vehicle for SARS-CoV-2 is still open and data are
20 controversial. Some studies reported presence of the virus in breast milk [6,7], although its
21 potential for infection is unclear [8]. Other studies found no presence of the virus in breast
22 milk [9–11]. In general, these studies showed several limitations, with the most relevant being
23 the lack of targeted and validated protocols for viral detection in milk matrix. Furthermore, a
24 rapid and strong antibody response is induced after SARS-CoV-2 maternal infection, with the
25 subsequent accumulation of substantial amounts of specific neutralizing secretory IgA (sIgA) in
26 breast milk [12]. Other studies have also reported presence of specific antibodies in milk
27 [7,13]. However, several questions still remain unanswered, including the extend of the
28 response and persistence of maternal antibodies in milk, and their potential protective role for
29 infants. Furthermore, exposure to other coronavirus might produce antibodies cross-reactive
30 to SARS-CoV-2 [14]. Under this scenario, our main objectives are 1) to provide scientific-base
31 evidence of the specific and reliable detection of SARS-CoV-2 in human milk; and 2) to
32 determine levels of reactive IgA, IgG, and IgM antibodies against the receptor binding domain
33 (RBD) of the spike protein and to the main protease (MPro) of SARS-CoV-2 in human milk
34 samples collected during the COVID-19 pandemic.

35

36 Material and Methods

37 Study population

38 This is a prospective observational, longitudinal, and multicenter study in mother-infant pairs
39 with confirmed SARS-CoV-2 infection (ClinicalTrials.gov Identifier: NCT04768244). Participants
40 were recruited from 7 health centers from different provinces in Spain (Valencia, Barcelona,
41 Granada, and Zaragoza). Recruitment period was from April to December 2020. Participants
42 were pregnant with intended breastfeeding and nursing women with positive PCR for SARS-
43 CoV-2 in nasopharynge or presence of SARS-CoV-2 antibodies in serum determined in
44 hospitals. Women were excluded when COVID-19 symptomatology required specific treatment

1 and/or hospitalization in intensive care units. All participants received oral and written
2 information about the study and written consent was obtained. All protocols performed in the
3 study were in accordance with the ethical standards approved by the Ethical Committee of the
4 Hospital Clínico Universitario of Valencia (Ref. 2020/133) and by the rest of the Ethical and
5 Research's Committees.

6 A control group of women not exposed to SARS-CoV-2 and from prepandemic time was
7 included. Those women were randomly selected from the MAMI birth cohort in Spain [15]
8 (ClinicalTrials.gov Identifier: NCT03552939). This protocol was approved by the Ethical
9 Committee of the Hospital Clínico Universitario of Valencia (Ref. 2015/0024) and by the local
10 Ethical Committee of Atención Primaria-Generalitat Valenciana (CEIC-APCV).

11

12 **Human milk collection and processing**

13 Breast milk collection was performed following a standardized protocol described elsewhere
14 [16]. In brief, breast skin was cleaned with water and soap and the first drops were discarded.
15 Then, milk was collected either by use of a sterile pump or manually extracted. Samples were
16 collected in sterile bottles to normalize collection among participants. Morning collection was
17 recommendable. Finally, breast milk samples were immediately stored at -20°C in deep
18 freezers and sent to the hospital to be stored at -80°C until further analysis.

19 Whole milk was used for SARS-CoV-2 RNA detection. Whey milk samples were used for
20 antibodies determination and were prepared as follows: samples were thawed and
21 centrifuged at 14,000 rpm at 4°C for 10 min to remove fat and the resulting supernatant was
22 transferred into new tubes. Centrifugation was repeated twice to ensure removal of all cells
23 and fat. Skimmed acellular milk was then aliquoted and frozen at -80°C until use. Prepandemic
24 control milk samples were stored at -80°C before processing exactly as described for COVID-19
25 milk samples.

26

27 **Validation of SARS-CoV-2 RNA extraction, detection, and quantification in breast milk** 28 **samples**

29 A manual column-based commercial kit (referred as MN) and an automated assisted method
30 based on magnetic beads (referred as Max) were adapted following previous
31 recommendations [17] and compared to assess their sensitivity for detecting viral particles in
32 breast

33 milk samples. Main modifications of providers' official protocols included: 150 μL of whole
34 breast milk were treated with Plant RNA Isolation Aid (Ambion, USA) prior to extraction with
35 MN (Nucleospin RNA virus Kit, Macherey-Nagel GmbH & Co., Germany), while 300 μL of whole
36 breast milk were used for nucleic acid isolation with Max (Maxwell[®] RSC Instrument coupled
37 with Maxwell RSC Pure Food GMO and authentication kit, Promega, Spain). RNA was finally
38 eluted in 100 μL nuclease-free water in both extraction protocols.

39 Initially, to characterize the viral recovery of both methods, porcine epidemic diarrhoea virus
40 (PEDV) strain CV777 (an enveloped virus member of the *Coronaviridae* family and surrogate for
41 SARS-CoV-2), and also, mengovirus (MgV) vMCO (CECT 100000, non-enveloped member of the
42 *Picornaviridae* designated in the ISO 15216-1:2017 standard method as process control) were
43 spiked in phosphate buffer solution (PBS) and also, in breast milk. Detection ratios and limits of
44 detection ($\text{LoD}_{95\%}$ and $\text{LoD}_{50\%}$) were also characterized for both extraction methods by spiking
45 serial dilutions of PEDV.

1 Finally, serially diluted viral suspensions of gamma irradiated SARS-CoV-2 (Bei Resources; NR-
2 52287), and human coronavirus (HCoV) 229E (ATCC-VR740) were used to further define the
3 analytical performances of Max extraction. Detection limits were calculated using the PODLOD
4 calculation program v.9 according to [18].

5 Viral RNA detection was performed by reverse transcription polymerase chain reactions (RT-
6 qPCR) using One Step PrimeScript™ RT-PCR Kit (Perfect Real Time) (Takara Bio, USA), targeting
7 the N1 region of the nucleocapsid gene for SARS-CoV-2 [19], the membrane gene for HCoV
8 229-E [20] and PEDV [21], and the region from 110 to 209 nucleotides for MgV [22]. The
9 human RNase P gene [19] was used as quality control parameter for extraction. Reaction
10 mixes, thermal cycling conditions, sequences for primers and probes, and standard
11 quantification curves are detailed elsewhere [17,21]. Those for HCoV 229-E detection are
12 included as supplementary material (Figure S1). Genome copies (gc) were calculated by using
13 standard curves of 10-fold serial dilutions of SARS-CoV-2 genomic RNA (ATCC VR-1986D) or
14 HCoV 229-E, PEDV and MgV suspensions in quintuplicates.

15 All RT-qPCR assays were performed in duplicate on a LightCycler 480 instrument (Roche
16 Diagnostics, Germany). Positive (genomic RNA), negative (nuclease-free water), and inhibition
17 (either 10-fold diluted RNA or RP gene) controls were included in each assay.

18

19 **Breast milk SARS-CoV-2-specific antibody detection**

20 Levels of antibodies directed to structural proteins as RBD of the SARS-CoV-2 spike protein and
21 to non-structural viral proteins as cysteine-like protease, also known as the main protease
22 (Mpro) or 3CLpro, were analyzed.

23 RBD-specific antibodies were determined using a previously published and validated ELISA
24 protocol for use in human plasma and serum samples [23,24], and was modified for its use in
25 human milk samples. RBD protein was produced under HHSN272201400008C and obtained
26 through BEI Resources, NIAID, NIH: Spike Glycoprotein RBD from SARS-CoV-2, Wuhan-Hu-1
27 with C-Terminal Histidine Tag, Recombinant from HEK293T Cells, NR-52946. Briefly, 96-well
28 ELISA immunoplates (Costar) were coated with RBD protein at 2 µg/mL and incubated at 4 °C
29 overnight. Coated plates were blocked in 3 % (w/v) milk powder in PBS containing 0.1 % Tween
30 20 (PBS-T) for 1 h. Then, 4-fold dilution of samples in 1 % (w/v) milk powder in PBS-T were
31 added, incubated for 2 h at room temperature and washed with PBS-T before addition of
32 horseradish peroxidase-conjugated secondary antibodies. For detection of the different
33 antibody isotypes, anti-human IgA (α-chain-specific) HRP antibody (Thermo-Fisher Scientific;
34 A18781; 1:6.000), anti-human IgM (µ-chain-specific) HRP antibody (Sigma-Aldrich; A0420;
35 1:4.000), and anti-human IgG (Fc specific) HRP antibody (Sigma-Aldrich; A0170; 1:4.000) were
36 used and incubated for 1 h in 1 % (w/v) milk powder in PBS-T. Bound antigen-specific
37 antibodies were detected with 100 µL 3,3',5,5'-Tetramethylbenzidine (TMB) and reactions
38 were stopped with 50 µL of 2M sulfuric acid. Absorbance at 450 nm was read in a ClarioStar
39 (BMG Labtech) microplate reader using the path length correction mode. For detection of
40 MPro-reactive antibodies, a commercial ELISA Kit (ImmunoStep, Salamanca, Spain) was used.
41 Samples were incubated 1:4 diluted, and remaining steps of the protocol were performed
42 according to manufacturer's instructions. For ELISA studies, milk samples were considered
43 positive when OD values from undiluted samples exceeded the positive cut-off values for each
44 assay and isotype calculated from pre-pandemic control samples and defined as the mean +/-
45 two standard deviations. Values from dilution curves were used for determining the area

1 under the curve (AUC) to get a better quantitative impression between COVID-19 and control
2 group. Endpoint titers were calculated from log-transformed titration curves using 4-
3 parameter non-linear regression function in GraphPad Prism 8.0 and the positive cut-off values
4 obtained from the prepandemic control group for each antigen and isotype.

5 6 **Breast milk Total IgA quantification**

7 Total IgA, including secretory IgA (sIgA), was measured in whey milk using a sandwich ELISA
8 quantitation kit from Bethyl Laboratories (Montgomery, TX) following the manufacturer's
9 instructions as previously detailed [25]. Briefly, an anti-human IgA antibody pre-adsorbed to
10 the plate allowed to capture the IgA, which was later detected by the addition of a biotinylated
11 detection antibody and streptavidin-conjugated horseradish peroxidase that catalyzed the
12 colorimetric reaction with the chromogenic substrate TMB. All milk whey samples were
13 analyzed at a 1:8,000 dilution. Data were expressed as mg/L of milk. Duplicate determinations
14 were performed on each plate.

15 16 **Statistical analysis**

17 Statistical analysis was performed in GraphPad Prism 8.0. After Shapiro-Wilk normality test,
18 non-parametric t-test (Mann-Whitney) was used to detect significant differences between
19 groups and Spearman correlation analysis to assess correlations between variables.

20 21 **Results**

22 **Study population characteristics**

23 A total of 60 mothers diagnosed with COVID-19 and 13 prepandemic were included in this
24 study. The maternal demographic and clinical characteristics of the COVID pandemic period
25 group (n=60) and the prepandemic group (n=13) are described in Table 1.

26 Among the 60 mothers, 52 were confirmed SARS-CoV-2 positive by PCR detection in
27 nasopharyngeal swabs while the other 8 mothers were seropositive (IgG positive). Most PCR
28 tests (38/52, 73.1%) were performed as part of routine surveillance before labor (Table 2).
29 Three mothers had positive PCR-results postnatally (on days 9, 217, and 517 after delivery) and
30 eight mothers had positive PCR results 72 h to 186 days prior to delivery. Out of the 8
31 seropositive mothers, 4 had a positive rapid antigen test within the month prior to delivery.
32 Samples from two different time points during lactation were available for 12 of the women
33 (<7 days and 15 days after delivery, approximately). Thus, a total of 72 breast milk samples
34 from infected women and 13 from control women were included in the study.

35 Most of the women (n=38 (63.3%)) were asymptomatic and the rest reported only mild COVID-
36 19 symptoms (pain, fatigue, or headache among others). No other effects or problems were
37 reported. All neonates were negative for SARS-CoV-2 and were all in good health.

38 39 **Validation of SARS-CoV-2 RNA extraction and detection methods in breast milk**

40 To optimize SARS-CoV-2 viral RNA detection in breast milk samples, an initial analytical
41 comparison aimed to determine the recovery of PEDV and MgV from spiked prepandemic
42 breast milk samples using manual (MN) and an automated (Max) extraction method.
43 Compared to spiked PBS, PEDV and MgV were recovered at 30 % (27-33 %) and 132 % (94-188
44 %) when extracted from whole milk samples with MN. Better recoveries (100 %) were
45 observed for both viruses extracted by Max. No significant inhibitions due to the milk matrix

1 were observed as depicted by cycle threshold (Ct) values of 10-fold diluted RNA or RP gene
2 reactions.

3 By spiking PEDV serial dilutions in milk samples, we further defined the detection ratios and
4 limits of detection (LoD_{95%} and LoD_{50%}) (Table 3). Results demonstrated similar sensibility of
5 both extraction methods being 10 and 13 PEDV gc/100µL the limit of detection with 95 %
6 confidence for MN and Max extraction methods, respectively. These results suggested
7 comparable analytical performances of both extraction methods for enveloped viruses, thus
8 the latter was further characterized by using gamma inactivated SARS-CoV-2 and HCoV 229-E,
9 along with PEDV and MgV, as the method intended to be used for screening breast milk
10 samples from COVID-19. LoD_{95%} resulted in values as low as 36, 209, 13, and 7 gc/100µL, and
11 LoD_{50%} in 8, 48, 3, 2 gc/100µL for SARS-CoV-2, HCoV 229-E, PEDV, and MgV, respectively
12 (Figure 1). Based on these analytical results, the Max method was selected to screen the 72
13 breast milk samples for the presence of SARS-CoV-2 RNA. Targeting the N1 and E regions, all
14 samples resulted negative for SARS-CoV-2 RNA presence. The RP gene used as quality control
15 excluded false negative results (Cq= 27.98 ± 3.04). From 2 of the 72 samples, we used all the
16 available volume for the PCR reaction and no remaining sample was available for following
17 analyses. Thus, 70 milk samples from 60 women were available for further research.

18

19 **SARS-CoV-2 reactive antibodies in breast milk**

20 To characterize the antibody response against SARS-CoV-2 in breast milk, we first tested
21 reactivity of IgA, IgM, and IgG to the RBD of the spike glycoprotein. Serial sample dilutions
22 were performed and both AUC and endpoint titers were calculated. Prepandemic milk samples
23 (n=13) served as controls and to determine positive cut-off values (Figure S2). Strong and
24 significant reactivity was found for IgA, IgM, and IgG from COVID-19 infected/recovered breast
25 milk and low levels of non-specific binding was observed for the prepandemic samples (Figure
26 2 a-c). When applying positive cut-off levels, 84.48 % (49/58) of the participating mothers
27 provided milk samples that tested positive for the RBD antigen at least in one of the three
28 antibody classes (Figure 2d) and in one of the repeated samples. When analyzing the 70
29 collected samples, 58 (82.9 %) were positive at least for one of the three antibody classes (IgA,
30 IgM or IgG). Thirty-seven milk samples (52.9 %) were positive for all three Igs, whereas 12
31 samples (17.1 %) did not show reactivity against RBD for any of the three antibody classes
32 (Figure 2e). In total, 51 samples were positive for IgA (72.9 %), 51 samples for IgM (72.9 %) and
33 45 samples for IgG (64.3 %). Among the samples that were positive for only one isotype, IgM
34 reactive RBD antibodies exceeded cut-off levels in 4 samples, whereas for IgG and IgA only one
35 sample showed reactivity against RBD for a unique isotype.

36 We corroborated our results using the MPro antigen, the main viral protease also known as
37 3CLPro as described elsewhere [26]. OD values of 1:4 diluted samples were grouped and
38 COVID-19 infected and recovered donors still showed significantly higher reactivity to the
39 MPro antigen (Figure 3). Noteworthy, positivity rate using this antigen decreased at this
40 dilution rate from 67.6 % to 42.3% for IgA and from 64.2 % to 31.3 % for IgG.

41 Since most of the mothers in our study were confirmed positive for SARS-CoV-2 as part of
42 routine surveillance prior to labor and therefore were asymptomatic, antibody response was
43 analyzed as a function of time since PCR-confirmation (Table 4). Positivity rate for IgA was
44 relatively stable over time (65.2–87.5 %). Most positive samples for IgM were detected when
45 collected at 11-20 days after PCR confirmation (83.3 %), and then levels consistently declined

1 to 62.5 %. IgG positivity rate continuously raised from 47.8 % to 87.5 % in samples collected
2 from day 41 up to day 206 post-PCR confirmation. In symptomatic COVID-19 cases, RBD-
3 specific IgA response was higher than in the asymptomatic group, although differences were
4 not significant, and no changes were detected in virus-specific IgM and IgG (Figure S3).
5 We compared endpoint titers of positive samples between the different antibody isotypes and
6 observed that the magnitude of response was similar in all three Igs (Figure 4). Furthermore,
7 all three Igs were significantly correlated to each other, particularly IgA and IgM ($r=0.7812$,
8 $p<0.0001$), but also IgA and IgG ($r=0.6100$, $p<0.0001$), and IgG and IgM ($r=0.5708$, $p=0.0001$).
9 A positive correlation ($r=0.5900$, $p=0.0001$) was also observed between total IgA levels and
10 SARS-CoV-2 specific antibody response (Figure 5a). In fact, total IgA levels were significantly
11 higher in the COVID-19 group when compared to the prepandemic controls (Figure 5b) and
12 could be part of the response to infection. In all the samples collected at different time points
13 within the first 20 days after birth, we observed this generalized decrease of IgA and endpoint
14 titers for RBD except in one mother, which exhibited low but raising antibody titers in
15 breastmilk (Figure 6). In our samples, total IgA concentrations correlated negatively with
16 lactational stage ($r=-0.3357$, $p=0.0045$), as well as with RBD-specific IgA ($r=-0.3088$, $p=0.0093$)
17 and IgM ($r=-0.4334$, $p=0.0002$), while the RBD-specific IgG response was independent of the
18 lactation stage. Furthermore, there was high inter- and intra-individual variability in the
19 antibody response to the virus for each of the three isotypes (Figure 7). Since most of the
20 donors were PCR-detected as part of birth COVID-19 protocol at hospitals, lactation stage and
21 the days elapsed since PCR detection coincided in a narrow time fragment; in fact, for 40 of the
22 positive tested samples in Figure 7a the difference was not more than 5 days between PCR-
23 detection and birth. Nevertheless, some individuals showed a long-lasting antibody response
24 and, in fact, two mothers which were positive PCR-tested 96 days (sample M39) and 186 days
25 (sample M61) before birth showed virus-specific-antibody titers for all three Igs, having the
26 highest levels for IgG. Regarding breastmilk samples from mothers confirmed with SARS-CoV-2
27 infection by serum serology (Figure 7b), seven out of the eight participants showed thoroughly
28 positive antibody responses for all three antibody classes, except one sample that was tested
29 negative for IgM. The sample that was negative for all three isotypes was from a mother with a
30 COVID-19 infection confirmed by serological testing 226 days prior to sample collection for our
31 study, with a 47-day old infant.

32

33 Discussion

34 During the current COVID-19 pandemic, science has primarily focused on providing solutions
35 and treatments against infection to reduce mortality. However, specific populations including
36 pregnant and lactating mothers as well as infants have not been widely considered. Thus,
37 there is a big gap in knowledge on maternal-infant health regarding COVID-19.

38 Breastfeeding is considered the most relevant postnatal link between mothers and infants,
39 being the best source of nutrition with effects for infant health and development. However,
40 the global COVID-19 pandemic and the lack of understanding of SARS-CoV-2 vertical
41 transmission [27] have considerably reduced breastfeeding practice. Even infected mothers
42 were recommended to temporarily separate from their infants [28].

43 In this prospective multicenter study, breast milk samples from women with COVID-19 were
44 collected and tested for SARS-CoV-2 RNA presence by RT-PCRs validated for breast milk
45 samples. It has been reported that DNA/RNA approaches could affect the detection of specific

1 organisms in milk [29]; furthermore, milk matrix could affect the efficiency on nucleic acids
2 recoveries [30,31] as we also identified. Thus, to facilitate the analysis, we chose whole milk to
3 test for viral RNA presence. To provide alternative options for SARS-CoV-2 RNA detection, both
4 a manual (MN) and an automated (Max) method were tested resulting in no significant
5 differences between them. Moreover, viral RNA limit of detection in breast milk spiked with
6 serial dilutions of a gamma inactivated SARS-CoV-2 stock were determined. The LoD95%
7 resulted as low as 36 gc/100µL and the LoD50% 8 gc/100µL. These data are in line with the
8 detection limit suggested by Chambers and colleagues where samples with >25 gc/100uL of
9 SARS-CoV-2 RNA would be considered positive, [32], although higher limit of ca. 10^{3-4} gc/100uL
10 was informed elsewhere [6]. Using Max extraction and SARS-CoV-2 detection by targeting the
11 N1 and gene E regions, we demonstrated that SARS-CoV-2 RNA was not present in the breast
12 milk samples tested.

13 Most of the bigger studies have been carried out in USA [7,8,32] and limited data are available
14 for the European region. A study in an Italian cohort with 14 mother-infant pairs [33] showed
15 that SARS-CoV-2 positive mothers do not transfer the virus during breastfeeding. Four
16 neonates from this study were also positive, suggesting other potential infection routes.
17 Another study in Germany with longitudinal samples from 2 women found some samples with
18 positive signal for viral RNA [6]. A recent systematic review reported 37 articles analyzing
19 breast milk samples on a total of 68 lactating mothers with COVID19 and SARS-CoV-2 RNA was
20 detected in 9 of the samples (9/68, 13.2%) [34]. Available data in recent literature showed that
21 around 2-6 % of milk samples would harbor viral RNA. A recent systematic review including
22 116 confirmed COVID-19 lactating women reported that the SARS-CoV-2 RNA detection in
23 human milk was 2.16 % [35]. The biggest study up to now included study, with 110 women in
24 USA (n=65 testing positive for SARS-CoV-2), showed that 6 % of the women had RNA presence
25 of SARS-CoV-2 in milk, however no infectious viral particles were isolated by cell culture [8].
26 Despite this evidence, lactating women should follow the recommendations of wearing a
27 mask, washing their hands during lactation, and avoiding droplets or aerosols that can infect
28 the neonate. In our study, we have not detected SARS-CoV-2 RNA in any of the breast milk
29 samples from participants in our study, contributing to the evidence that there is no vertical
30 transmission during breastfeeding. Our study represents one of the biggest studies in Europe
31 and the first in Spain. Currently, there is no evidence of SARS-CoV-2 transmission through
32 breast milk. Regarding the potential limitations, we did not collect skin swabs to control for the
33 potential presence of SARS-CoV-2 in the skin [7,33]. However, all milk samples as well as the
34 infants were negative for SARS-CoV-2 presence. Thus, although there are still limited data, it is
35 accepted that breastfeeding does not represent a vehicle for vertical transmission of SARS-
36 CoV-2 [9]. There are still many open questions: when are SARS-CoV-2 antibodies produced
37 after maternal infection, when can they be detected in breast milk, and how long do they
38 persist. To cover some of these questions, we aimed to determine the presence of antibodies
39 in breast milk samples from COVID-19 women and to compare these with milk samples
40 collected prior to the pandemic as reference controls.

41 While different studies have reported presence of specific IgA antibodies against SARS-CoV-2
42 [7,12,13,36], limited information is available on IgG and IgM. Our results showed presence of
43 anti-SARS-CoV-2 antibodies in milk, primarily IgA but also IgG and IgM targeting RBD.
44 Furthermore, IgA- and IgG against non-structural MPro were analyzed for the first time in
45 human milk samples. High intra- and inter-individual variability was observed in antibody

1 presence and significant differences were observed for all three antibody classes when
2 compared to prepandemic samples in agreement with previous data [26]. In our dataset we
3 found that 82.9 % of the milk samples tested positive for the RBD antigen at least in one of the
4 three antibody isotypes and 52.86 % were positive in all three Igs. Interestingly, 12 samples
5 (17.14 %) did not show reactivity against the RBD region in any of the three antibody classes.
6 Endpoint titers for all three antibody classes were in the same range and correlated
7 significantly. We could not detect time-dependent quantitative differences in endpoint titers
8 for the different antibody classes, due to high interindividual variability. However, we found a
9 time-dependent increase from 47.8 % to 87.5 % in IgG-positive samples collected from day 41
10 up to day 206 post-PCR confirmation. These data are in line with findings in human serum
11 samples from a Chinese cohort showing persistence of IgG up to 6 months in at least 90 % of
12 confirmed cases [37]. To date, only a few studies have quantified virus-specific antibodies and
13 compared them to prepandemic samples in order to establish cut-off values to discriminate
14 between positive and negative samples [7,12,38], which allows the comparison of results
15 between studies. We found similar proportion of positive samples for both IgA, from 72.9 % in
16 our study to 80.0 % [7,12] and IgM, 72.9 % in our study compared to 55.0 % in the study
17 reported by Peng and colleagues [38].

18 In this study, we also assessed presence of antibodies against other nonstructural viral
19 proteins, specifically the viral cysteine-like protease, also known as 3CLPro or main viral
20 protease (MPro), as described elsewhere [26]. Our data showed presence of anti-MPro IgA and
21 IgG antibodies in milk samples from COVID-19 women compared to prepandemic samples,
22 although the sensitivity was lower than when using the RBD antigen for detection of virus-
23 specific antibodies. MPro is a viral antigen not exposed on the viral particle as this is the case
24 of the spike protein, however, strong and similar reactivities were found for both MPro, RBD,
25 and the nucleocapsid protein in serum and saliva samples [26]. Our study is the first using
26 MPro for detection of SARS-Cov-2 antibodies in human milk, and the different reactivities to
27 the different viral antigens, also in function of isotype, have been previously reported in
28 human milk samples [7,33].

29 It is known that human milk contains a wide variety of Igs, with IgA representing the majority
30 (80 to 90%). Secretory IgA (sIgA) is the predominant immunoglobulin class in human milk,
31 representing about 90% of the total Igs present in human milk [39]. Our data showed positive
32 associations between total IgA levels in milk and COVID-19 specific antibody responses. In fact,
33 total IgA levels were significantly higher in the COVID-19 group when compared to the
34 prepandemic controls, possibly due to the response to the infection. Total IgA concentrations
35 in human milk change over time during the lactation period, with levels decreasing from
36 colostrum to mature milk [40]. In this line, in samples collected at different time points within
37 the first 20 days after birth, we observed this generalized decrease of IgA and endpoint titers
38 for RBD, except in one mother, which noteworthy exhibited low but raising antibody titers in
39 breast milk.

40 Our results are in agreement with previous data showing higher levels of antibodies against
41 SARS-CoV-2 in milk compared to samples from women before the pandemic [36,41]. However,
42 prepandemic samples showed some reactivity to SARS-CoV-2, which may be explained by
43 cross-reaction with other seasonal coronavirus (HCoV) as previously reported [14]. It has been
44 demonstrated that viral infections influence the antibody response in milk [42]. In addition, a
45 recent study reported higher S1 + S2-reactive IgG in breast milk from women that had viral

1 respiratory infection symptoms before pandemic than in milk from women without symptoms
2 [36]. These data would partially explain the potential signal or cross-reactivity in breast milk
3 samples before 2020.

4 Furthermore, SARS-CoV-2 IgA levels are higher in human breast milk than in maternal plasma
5 while IgG and IgM levels are lower [43], suggesting potential active local production as
6 reported for other virus including rotavirus [44]. We observed that women with COVID-19
7 symptoms showed slightly higher virus-specific IgA levels in milk compared to women with
8 asymptomatic infection, although differences were not significant. Moreover, no differences
9 in IgM or IgG levels were found, possibly due to minor COVID-19 symptoms (pain, headache,
10 etc.) in this data set. Despite these observations, further analysis including a bigger sample
11 size and different symptoms as well as severe COVID-19 infected donors are warranted.
12 Regarding breastmilk samples from mothers confirmed COVID-19 by serum serology, only 1
13 out of 8 samples was negative for all three isotypes, possibly due to the time elapsed (226
14 days) between serological testing and sample collection.

15 In summary, our study demonstrates 1) absence of SARS-CoV-2 in breast milk from women
16 with COVID-19; and 2) high inter- and intra-variability in SARS-CoV-2 antibody response.
17 Women with a positive PCR or serology exhibited IgA, IgG, and IgM antibodies in breast milk
18 not only against structural proteins like RBD but also against non-structural proteins like MPro.
19 Presence of IgM in some samples suggests that breast milk might have a protective effect on
20 newborns. Interestingly, positive associations between total IgA and specific antibodies (IgA,
21 IgG and IGM) were observed, although their persistence and stability differed between
22 mothers and antibody type. Our study endorses the safety of breastfeeding practices and
23 highlights the potential relevance of virus-specific SARS-CoV-2 antibodies providing passive
24 immunity to breastfeeding infants protecting them against COVID-19.

25 This study provides scientific evidence to support official recommendations stating
26 breastfeeding safety during the COVID-19 pandemic, indicating that breastfeeding should be a
27 priority with potential benefit for both mothers and neonates.

28

29 **Acknowledgements:**

30 We thank all the families who were involved in the study during this difficult time and in the
31 middle of the COVID19 pandemic as well as the collaborators of the MilkCORONA (detailed
32 below), which includes neonatologists, pediatricians, midwives, nurses, research scientists, and
33 computer/laboratory technicians. This study represents a cooperative effort between different
34 groups in Spain.

35

36 MilkCORONA Collaborators:

- 37 ii) Elena Crehuá-Gaudiza (Pediatrician, MD, PhD), Javier Estañ-Capell (Pediatrician, MD, PhD)
38 from Pediatric Nutrition Research Group of INCLIVA Biomedical Research Institute of
39 Valencia and Department of Pediatrics, Hospital Clínico Universitario, University of
40 Valencia, Spain.
41 iii) Asuncion Obiol (midwife, PhD), Reyes Balanza (MD, PhD), Department of Gynecology and
42 Obstetrics, Hospital Universitario Dr. Peset, Valencia, Spain
43 iv) Álvaro Solaz-García (RN), Inmaculada Lara-Cantón (MD), Health Research Institute La Fe,
44 Neonatal Research Group, Spain and University and Polytechnic Hospital La Fe, Division of
45 Neonatology, Valencia, Spain.

- 1 vi) Cristina Garcia (MSc), Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu,
2 Barcelona, Spain.
- 3 viii) María Ríos Barnés (pediatrician, MD) Infectious Diseases Unit. Pediatrics Department,
4 Hospital Sant Joan de Déu, Barcelona, Spain.
- 5 ix) Sara Ruiz (MD, PhD), Marta Fabre (MD, PhD), Hospital Clínico Universitario Lozano Blesa,
6 Zaragoza. Instituto de Investigación Sanitaria Aragón (IIS Aragón),
7 x) Federico García-García (MD, PhD) Department of Microbiology. University Clinical Hospital
8 San Cecilio, Granada and BioHealth Research Institute (Ibs), Granada, Health Sciences
9 Technological Park, Granada, Spain.
- 10 xi) Maria José Rodríguez-Lagunas (PhD), Karla Río-Aigé (MSc), Physiology Section, Department
11 of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of
12 Barcelona (UB), Barcelona, Spain and Nutrition & Food Safety Research Institute (INSA-UB),
13 08921 Santa Coloma de Gramenet, Spain.

14
15

16 Contributions

17 Study concept and design: CMC and MCC. Drafting of the manuscript: CB, WR, CMC and MCC.
18 Clinical aspects including recruitment of the participants, collection of samples and medical
19 records: CMC, LMR, APLI, EGV, CL, VF, FC, FC, GR, CC, GRR. Sample management, processing,
20 and analysis: CB, WR, MSR, GS, FJPC, MCC. All authors read and approved the final manuscript.

21

22 References

- 23 [1] Tromp I, Kieft-de Jong J, Raat H, Jaddoe V, Franco O, Hofman A, et al. Breastfeeding and the risk
24 of respiratory tract infections after infancy: The Generation R Study. *PLoS One* 2017;12:e0172763.
25 <https://doi.org/10.1371/journal.pone.0172763>.
- 26 [2] Wang J, Ramette A, Jurca M, Goutaki M, Beardsmore CS, Kuehni CE. Breastfeeding and respiratory
27 tract infections during the first 2 years of life. *ERJ Open Res* 2017;3.
28 <https://doi.org/10.1183/23120541.00143-2016>.
- 29 [3] Christensen N, Bruun S, Søndergaard J, Christesen HT, Fisker N, Zachariassen G, et al.
30 Breastfeeding and Infections in Early Childhood: A Cohort Study. *Pediatrics* 2020;146.
31 <https://doi.org/10.1542/peds.2019-1892>.
- 32 [4] Frank NM, Lynch KF, Uusitalo U, Yang J, Lönnrot M, Virtanen SM, et al. The relationship between
33 breastfeeding and reported respiratory and gastrointestinal infection rates in young children. *BMC*
34 *Pediatr* 2019;19:339. <https://doi.org/10.1186/s12887-019-1693-2>.
- 35 [5] WHO | Infant and young child feeding. WHO n.d.
36 http://www.who.int/maternal_child_adolescent/documents/9789241597494/en/ (accessed April
37 27, 2021).
- 38 [6] Groß R, Conzelmann C, Müller JA, Stenger S, Steinhart K, Kirchhoff F, et al. Detection of SARS-CoV-
39 2 in human breastmilk. *Lancet* 2020;395:1757–8. [https://doi.org/10.1016/S0140-6736\(20\)31181-8](https://doi.org/10.1016/S0140-6736(20)31181-8).
- 40 [7] Pace RM, Williams JE, Järvinen KM, Belfort MB, Pace CDW, Lackey KA, et al. Characterization of
41 SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-
42 19. *MBio* 2021;12. <https://doi.org/10.1128/mBio.03192-20>.
- 43 [8] Krogstad P, Contreras D, Ng H, Tobin N, Chambers CD, Bertrand K, et al. No Evidence of Infectious
44 SARS-CoV-2 in Human Milk: Analysis of a Cohort of 110 Lactating Women. *MedRxiv* 2021.
45 <https://doi.org/10.1101/2021.04.05.21254897>.
- 46 [9] Bhatt H. Should COVID-19 Mother Breastfeed her Newborn Child? A Literature Review on the
47 Safety of Breastfeeding for Pregnant Women with COVID-19. *Curr Nutr Rep* 2021.
48 <https://doi.org/10.1007/s13668-020-00343-z>.
- 49 [10] Lackey KA, Pace RM, Williams JE, Bode L, Donovan SM, Järvinen KM, et al. SARS-CoV-2 and human
50 milk: What is the evidence? *Matern Child Nutr* 2020;16:e13032.
51 <https://doi.org/10.1111/mcn.13032>.
- 52

- 1 [11] Rodrigues C, Baía I, Domingues R, Barros H. Pregnancy and Breastfeeding During COVID-19
2 Pandemic: A Systematic Review of Published Pregnancy Cases. *Front Public Health* 2020;8:558144.
3 <https://doi.org/10.3389/fpubh.2020.558144>.
- 4 [12] Fox A, Marino J, Amanat F, Oguntuyo K, Hahn-Holbrook J, Lee B, et al. The Spike-specific IgA in
5 milk commonly-elicited after SARS-Cov-2 infection is concurrent with a robust secretory antibody
6 response, exhibits neutralization potency strongly correlated with IgA binding, and is highly
7 durable over time. *MedRxiv* 2021:2021.03.16.21253731.
8 <https://doi.org/10.1101/2021.03.16.21253731>.
- 9 [13] Favara DM, Ceron-Gutierrez ML, Carnell GW, Heeney JL, Corrie P, Doffinger R. Detection of
10 breastmilk antibodies targeting SARS-CoV-2 nucleocapsid, spike and receptor-binding-domain
11 antigens. *Emerg Microbes Infect* 2020;9:2728–31.
12 <https://doi.org/10.1080/22221751.2020.1858699>.
- 13 [14] Demers-Mathieu V, DaPra C, Mathijssen G, A Sela D, M Jarvinen K, Seppo A, et al. Human Milk
14 Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers
15 with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers. *Int J Mol Sci*
16 2021;22. <https://doi.org/10.3390/ijms22041749>.
- 17 [15] García-Mantrana I, Alcántara C, Selma-Royo M, Boix-Amorós A, Dzidic M, Gimeno-Alcañiz J, et al.
18 MAMI: a birth cohort focused on maternal-infant microbiota during early life. *BMC Pediatr*
19 2019;19:140. <https://doi.org/10.1186/s12887-019-1502-y>.
- 20 [16] McGuire MK, Seppo A, Goga A, Buonsenso D, Collado MC, Donovan SM, et al. Best Practices for
21 Human Milk Collection for COVID-19 Research. *Breastfeed Med* 2021;16:29–38.
22 <https://doi.org/10.1089/bfm.2020.0296>.
- 23 [17] Pérez-Cataluña A, Cuevas-Ferrando E, Randazzo W, Falcó I, Allende A, Sánchez G. Comparing
24 analytical methods to detect SARS-CoV-2 in wastewater. *The Science of the Total Environment*
25 2021;758:143870. <https://doi.org/10.1016/j.scitotenv.2020.143870>.
- 26 [18] Wilrich C, Wilrich P-T. Estimation of the pod function and the LOD of a qualitative microbiological
27 measurement method. *Journal of AOAC International* 2009;92:1763–72.
28 <https://doi.org/10.1093/jaoac/92.6.1763>.
- 29 [19] CDC. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. CDC 2019-Novel
30 Coronavirus (2019-NCoV) Real-Time RT-PCR Diagnostic Panel 2020.
- 31 [20] Vijgen L, Keyaerts E, Moës E, Maes P, Duson G, Van Ranst M. Development of one-step, real-time,
32 quantitative reverse transcriptase PCR assays for absolute quantitation of human coronaviruses
33 OC43 and 229E. *Journal of Clinical Microbiology* 2005;43:5452–6.
34 <https://doi.org/10.1128/JCM.43.11.5452-5456.2005>.
- 35 [21] Puente H, Randazzo W, Falcó I, Carvajal A, Sánchez G. Rapid Selective Detection of Potentially
36 Infectious Porcine Epidemic Diarrhea Coronavirus Exposed to Heat Treatments Using Viability RT-
37 qPCR. *Frontiers in Microbiology* 2020;11:1911.
- 38 [22] 15216-1 ISO. Microbiology of food and animal feed—Horizontal method for determination of
39 Hepatitis A Virus and norovirus in food using real-time RT-PCR—Part 1. Method for Quantification
40 2017;Vol. 15216.
- 41 [23] Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A
42 serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* 2020;26:1033–6.
43 <https://doi.org/10.1038/s41591-020-0913-5>.
- 44 [24] Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2
45 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and
46 Test Setup. *Curr Protoc Microbiol* 2020;57:e100. <https://doi.org/10.1002/cpmc.100>.
- 47 [25] Permanyer M, Castellote C, Ramírez-Santana C, Audí C, Pérez-Cano FJ, Castell M, et al.
48 Maintenance of breast milk Immunoglobulin A after high-pressure processing. *J Dairy Sci*
49 2010;93:877–83. <https://doi.org/10.3168/jds.2009-2643>.
- 50 [26] Martínez-Fleta P, Alfranca A, González-Álvaro I, Casanovas JM, Fernández-Soto D, Estes G, et al.
51 SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19-
52 Seropositive Individuals. *J Immunol* 2020;205:3130–40.
53 <https://doi.org/10.4049/jimmunol.2000842>.
- 54 [27] Crovetti F, Crispi F, Llurba E, Pascal R, Larroya M, Trilla C, et al. Impact of SARS-CoV-2 Infection on
55 Pregnancy Outcomes: A Population-Based Study. *Clinical Infectious Diseases* 2021.
56 <https://doi.org/10.1093/cid/ciab104>.

- 1 [28] Latorre G, Martinelli D, Guida P, Masi E, De Benedictis R, Maggio L. Impact of COVID-19 pandemic
2 lockdown on exclusive breastfeeding in non-infected mothers. *Int Breastfeed J* 2021;16:36.
3 <https://doi.org/10.1186/s13006-021-00382-4>.
- 4 [29] Douglas CA, Ivey KL, Papanicolas LE, Best KP, Muhlhausler BS, Rogers GB. DNA extraction
5 approaches substantially influence the assessment of the human breast milk microbiome.
6 *Scientific Reports* 2020;10:123. <https://doi.org/10.1038/s41598-019-55568-y>.
- 7 [30] Taylor TM, Elhanafi D, Drake M, Jaykus L-A. Effect of food matrix and cell growth on PCR-based
8 detection of *Escherichia coli* O157:H7 in ground beef. *J Food Prot* 2005;68:225–32.
9 <https://doi.org/10.4315/0362-028x-68.2.225>.
- 10 [31] Sajali N, Wong SC, Hanapi UK, Jamaluddin SAB@, Tasrip NA, Desa MNM. The Challenges of DNA
11 Extraction in Different Assorted Food Matrices: A Review. *Journal of Food Science* 2018;83:2409–
12 14. <https://doi.org/10.1111/1750-3841.14338>.
- 13 [32] Chambers C, Krogstad P, Bertrand K, Contreras D, Tobin NH, Bode L, et al. Evaluation for SARS-
14 CoV-2 in Breast Milk From 18 Infected Women. *JAMA* 2020;324:1347–8.
15 <https://doi.org/10.1001/jama.2020.15580>.
- 16 [33] Bertino E, Moro GE, De Renzi G, Viberti G, Cavallo R, Coscia A, et al. Detection of SARS-CoV-2 in
17 Milk From COVID-19 Positive Mothers and Follow-Up of Their Infants. *Front Pediatr*
18 2020;8:597699. <https://doi.org/10.3389/fped.2020.597699>.
- 19 [34] Centeno-Tablante E, Medina-Rivera M, Finkelstein JL, Rayco-Solon P, Garcia-Casal MN, Rogers L, et
20 al. Transmission of SARS-CoV-2 through breast milk and breastfeeding: a living systematic review.
21 *Ann N Y Acad Sci* 2021;1484:32–54. <https://doi.org/10.1111/nyas.14477>.
- 22 [35] Kumar J, Meena J, Yadav A, Kumar P. SARS-CoV-2 detection in human milk: a systematic review. *J*
23 *Matern Fetal Neonatal Med* 2021:1–8. <https://doi.org/10.1080/14767058.2021.1882984>.
- 24 [36] Demers-Mathieu V, Do DM, Mathijssen GB, Sela DA, Seppo A, Järvinen KM, et al. Difference in
25 levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and
26 SIgA/IgA antibodies in human milk. *Journal of Perinatology* 2021;41:850–9.
27 <https://doi.org/10.1038/s41372-020-00805-w>.
- 28 [37] He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of
29 anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional
30 study. *Lancet* 2021;397:1075–84. [https://doi.org/10.1016/S0140-6736\(21\)00238-5](https://doi.org/10.1016/S0140-6736(21)00238-5).
- 31 [38] Peng S, Zhu H, Yang L, Cao L, Huang X, Dynes M, et al. A study of breastfeeding practices, SARS-
32 CoV-2 and its antibodies in the breast milk of mothers confirmed with COVID-19. *The Lancet*
33 *Regional Health – Western Pacific* 2020;4. <https://doi.org/10.1016/j.lanwpc.2020.100045>.
- 34 [39] Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. *Nutrients*
35 2011;3:442–74. <https://doi.org/10.3390/nu3040442>.
- 36 [40] Affolter M, Garcia-Rodenas CL, Vinyes-Pares G, Jenni R, Roggero I, Avanti-Nigro O, et al. Temporal
37 Changes of Protein Composition in Breast Milk of Chinese Urban Mothers and Impact of
38 Caesarean Section Delivery. *Nutrients* 2016;8. <https://doi.org/10.3390/nu8080504>.
- 39 [41] Keulen BJ van, Romijn M, Bondt A, Dingess KA, Kontopodi E, Straten K van der, et al. Breastmilk; a
40 source of SARS-CoV-2 specific IgA antibodies. *MedRxiv* 2020:2020.08.18.20176743.
41 <https://doi.org/10.1101/2020.08.18.20176743>.
- 42 [42] Ehlinger EP, Webster EM, Kang HH, Cangialose A, Simmons AC, Barbas KH, et al. Maternal
43 cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus
44 transmission in very low-birth-weight preterm infants. *J Infect Dis* 2011;204:1672–82.
45 <https://doi.org/10.1093/infdis/jir632>.
- 46 [43] Demers-Mathieu V, DaPra C, Medo E. Comparison of Severe Acute Respiratory Syndrome
47 Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from
48 Coronavirus Disease 2019-Recovered Women. *Breastfeed Med* 2021.
49 <https://doi.org/10.1089/bfm.2020.0381>.
- 50 [44] Asensi MT, Martínez-Costa C, Buesa J. Anti-rotavirus antibodies in human milk: quantification and
51 neutralizing activity. *J Pediatr Gastroenterol Nutr* 2006;42:560–7.
52 <https://doi.org/10.1097/01.mpg.0000221892.59371.b3>.
- 53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Table 1: Characteristics of the volunteers included in the study

	COVID-19 (n=60)	Prepandemic Control (n=13)	p-value
Maternal characteristics:			
Age	34.8 ± 4.6 ¹⁾	33.8 ± 4.2	0.4827 ^a
Gestational age (weeks)*	39.2 (38.1 – 40.6) ²⁾	39 (39.0 – 40.0)	0.9631 ^a
Delivery mode, n (%) ³⁾			0.3062 ^c
Vaginal	42 (76.4 %)	8 (61.5 %)	
Cesarean section	13 (23.6 %)	5 (38.5 %)	
Infant characteristics:			
Birth weight (g)	3247 ± 519 ⁴⁾	3323 ± 475.7	0.6296 ^a
Birth length (cm)	49.8 ± 2.4 ⁵⁾	50.5 ± 1.6	0.2958 ^a
Breastfeeding status ⁶⁾			0.7558 ^c
Exclusive	35 (66.0 %)	8 (61.5 %)	
Mixed feeding	18 (34.0 %)	5 (38.5 %)	
Gender ⁷⁾			0.5333 ^c
Male	24 (44.4 %)	4 (30.8 %)	
Female	30 (55.6 %)	9 (69.2 %)	

* Values are given as median and 25th and 75th percentile

^a Unpaired t-test

^b Mann-Whitney test

^c Fisher's exact test (two-sided)

Missing data from ¹⁾ 4 individuals; ²⁾ 10 individuals; ³⁾ 5 individuals; ⁴⁾ 8 individual; ⁵⁾ 14 individuals; ⁶⁾ 7 individuals;

⁷⁾ 6 individuals

1
2
3
4
5
6
7
8

Table 2: COVID-19 related data and sample characteristics

COVID-19 diagnosis:	n=60
Positive nasopharyngeal PCR confirmation	n=52
confirmation 48 h before delivery	38
confirmation 48 h after delivery	2
confirmation > 48 h before delivery	9
confirmation > 48 h after delivery	3
Positive serology confirmation	n=8
confirmation 48 h before/after delivery	3
confirmation > 48 h before delivery	1
confirmation > 48 h after delivery	4
COVID-19 symptomatology	
Symptomatic prior or at enrollment	22
Average time from COVID-19 diagnosis to breast milk sample collection	
Days post-PCR confirmation *	15.0 (6.0 – 29.8)
Days post-serology confirmation *	15.5 (2.0 – 40.5)

9 * Values are given as median and 25th and 75th percentile

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

1
2
3
4
5
6
7
8
9
10
11

Table 3. Concentrations, detection ratios and limits of detection (LoD_{95%} and LoD_{50%}) characterizing the analytical performances of a manual commercial kit (MN) and an automated assisted method (Max) to extract porcine epidemic diarrhoea virus (PEDV) spiked in breast milk

Levels of inoculated PEDV (gc/100uL)	MN				Max			
	Back calculated concentration (gc/100uL ± SD)	Detection ratio (+/total)	LoD ₉₅ (gc/100 uL)	LoD ₅₀ (gc/100 uL)	Back calculated concentration (gc/100uL ± SD)	Detection ratio (+/total)	LoD ₉₅ (gc/100 uL)	LoD ₅₀ (gc/100 uL)
10e3	1348.84 ± 152.84	6/6			3137.92 ± 756.22	6/6		
10e2	196.52 ± 10.10	6/6			575.86 ± 346.03	6/6		
10e1	25.82 ± 5.03	6/6	10.0	2.96	92.94 ± 44.48	6/6	13.38	3.10
10e0	2.05 ± 0.25	2/6			16.39 ± 4.45	3/6		
10e-1	-	0/6			-	0/6		

12
13
14
15
16
17
18
19
20
21
22
23
24

1

2

3

4 **Table 4: Positive samples and rates of virus-RBD specific antibodies versus days of positive**
5 **PCR confirmation**

6

* / Days post-PCR	0-10d (n=23)	11-20d (n=18)	21-40d (n=13)	41-206d (n=8)
IgA	15 (65.2 %)	13 (72.2 %)	9 (69.2 %)	7 (87.5 %)
IgM	18 (78.3 %)	15 (83.3 %)	7 (53.9 %)	5 (62.5 %)
IgG	11 (47.8 %)	10 (55.6 %)	10 (76.9 %)	7 (87.5 %)

7 *Number of breast milk samples with positive results and percentage.

8

9




Figure 1. Distribution of cycle threshold values (Cq) characterizing the limits of detection of the automated assisted method (Max) to extract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human coronavirus 229E (HCoV 229-E), porcine epidemic diarrhea virus (PEDV), and mengovirus (MgV) spiked in breast milk. The numbers above viral series denotes the LoD_{95%} (gc/100uL) for each virus.




Figure 2: Reactivity of human milk samples from COVID-19 infected and/or recovered mothers and prepandemic controls to RBD antigen. AUC were calculated from titration curves for RBD-reactive (a) IgA, (b) IgM, and (c) IgG in order to get a better graphical impression. Asterisks show statistically significant differences between groups (***p < 0.0001) using the Mann–Whitney test (unpaired nonparametric test). (d) Proportion of human milk donors who had positive RBD-reactive Igs in at least one milk recollection point, and negative samples (e) Proportion of RBD-reactive positive and negative human milk samples subdivided according to different isotypes.




Figure 3: Samples from infected milk donors show significantly higher binding to SARS-Cov-2 antigens compared to prepandemic control. Grouped OD values of 1:4 diluted samples of RBD- (a) and MPro- (b) reactive IgA, and RBD- (c) and MPro- (d) reactive IgG, respectively. Asterisks show statistically significant differences between groups (** $p < 0.0001$, * $p < 0.05$) using the Mann-Whitney test (unpaired nonparametric test).




Figure 4: Endpoint titers and correlation analysis between RBD-specific binding of antibody subclasses. (a) Grouped endpoint titers of the three different isotypes. Spearman's correlation analysis of endpoint titers between (a) RBD-specific IgA and RBD-IgM, (b) RBD-IgA and RBD-IgG, and (c) RBD-IgM and RBD-IgG.




Figure 5: Total IgA concentration and virus specific antibody response.

(a) Spearman's correlation analysis of total IgA concentration and virus specific IgA response expressed as AUC. (b) Total IgA in COVID-19 infected and recovered and prepandemic control samples.




Figure 6: Temporal dynamic changes of endpoint titers for RBD-specific Igs. IgA (red circles), IgM (blue squares) and IgG (green triangles). All isotypes were tested for RBD binding in both time points, only positive endpoint titer are drawn in the graphs, the absence of data in a given time point indicates samples that were below the Cut-off values and considered negative.




Figure 7: Individual endpoint titers of virus-specific antibodies in breast milk from SARS-Cov-2 infected and/or recovered mothers. (a) Endpoint titers of milk samples tested positive at least in one of the isotypes IgA, IgM and IgG are shown, ordered as days post-PCR. (B) Endpoint titers of milk samples tested positive at least in one of the isotypes IgA, IgM, and IgG are shown, ordered as days post-serology.